Navigation Links
Interventional Cardiology Devices: World Market Prospects 2011-2021
Date:11/2/2011

NEW YORK, Nov. 2, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Interventional Cardiology Devices: World Market Prospects 2011-2021

http://www.reportlinker.com/p0663863/Interventional-Cardiology-Devices-World-Market-Prospects-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

Our latest pharma report - Interventional Cardiology Devices: World Market Prospects 2011-2021 - offers a comprehensive view of the global interventional cardiology devices market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the interventional cardiology devices market in 2011 to be worth $10.6bn. Growth in this market will be driven by new technology such as, bioabsorbable stents, drug-eluting balloons and optical coherence tomography.

Interventional cardiology is one of the fastest growing sectors of the medical device market. Interventional cardiology is a branch of cardiology that deals with catheter based treatments of heart diseases and defects. This involves insertion of a catheter usually into the femoral artery. However, it is possible to use any large peripheral artery or vein. The market has significant potential for growth with the increasing global burden of coronary artery disease, especially in the emerging economies.

Visiongain's research suggests that the interventional cardiology devices market will benefit from the growth of healthcare markets in the emerging economies. Increasing wealth in China and India will lead to an increase in lifestyle related disorders such as diabetes and coronary artery disease. At the same time, mature markets such as theUS and Japan will also experience growth, albeit slow, restrained by some regulatory and reimbursement issues discussed in detail in the report.

Interventional Cardiology Devices: World Market Prospects 2011-2021 examines the coronary stent, PTCA balloon and intravascular imaging markets, with respect to the market size, leading companies and products, and promising products in the pipeline. Visiongain predicts that this market will grow steadily to 2021, primarily driven by technological innovation and new products reaching the market.

How will the interventional cardiology devices market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the interventional cardiology devices submarkets are growing most strongly? Who are the leading companies in the interventional cardiology devices market? What are the most promising interventional cardiology devices in development and when are they expected to receive market approval?

Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.

Detailed analysis of the global Interventional Cardiology Devices Market

Interventional Cardiology Devices: World Market Prospects 2011-2021 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are 93 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. 

Why you should buy Interventional Cardiology Devices: World Market Prospects 2011-2021

In this report, you will receive the following benefits in particular:

• You will receive our assessment of the current market for interventional cardiology devices, with respect to the leading segments, products, companies and national markets

• You will discover sales trends for the overall interventional cardiology devices market from 2011 to 2021 - seeing where commercial growth will occur

• You will discover sales trends for the main segments - coronary stents, PTCA balloons and intravascular imaging markets - from 2011 to 2021, with detailed discussions of market potential

• You will receive sales forecasts for leading geographical markets (US, Japan,Germany, France, Italy, Spain, UK, China and India), with informed discussion

• You will assess leading companies in the interventional cardiology devices market along with rankings for each company, with regards to global sales in 2010

• You will receive our analyses of the future of interventional cardiology devices market, including assessment of the R&D pipelines in the coronary stent, PTCA balloon and intravascular imaging segments

• You will examine the strengths, weaknesses, opportunities and threats (SWOT analysis) facing the coronary stent, PTCA balloon and intravascular imaging markets from 2011 onwards

• You will be able to investigate competition and opportunities influencing the interventional cardiology devices market from 2011 onwards

• You will see what will stimulate and restrain the interventional cardiology devices market from 2011

• You will discover the unmet needs in the market, driving the growth from 2011 onwards

• You will view expert opinion from our survey, including full interview transcripts.

You can obtain this report today

Anybody with an interest in the interventional cardiology industry should gain valuable information and insight from this new study by Visiongain, which analyses one of the most important cardiology devices industries. Success in the cardiology devices market from 2011 to 2021 will be characterised by the growth of interventional cardiology devices market and launch of innovative products currently in the pipeline. You can find out about the developments in this industry and much more from this latest report from visiongain on Interventional Cardiology Devices: World Market Prospects 2011-2021. You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6 

Table of Contents

1. Executive Summary

1.1 Interventional Cardiology Devices Market Review

1.2 Overview of Chapter Content

1.3 Research and Analysis Method

1.4 Glossary of Terms Relating to Interventional Cardiology

2. Introduction to Interventional Cardiology

2.1 What is Interventional Cardiology?

2.1.1 Advantages and Disadvantages of Interventional Cardiology

2.2 Coronary Artery Disease (CAD)

2.3 Interventional Cardiology Procedures

2.3.1 Angioplasty

2.3.1.1 Balloon Angioplasty

2.3.1.2 Laser Angioplasty

2.3.2 Coronary Stenting

2.3.2.1 Bare Metal Stents (BMS)

2.3.2.2 Drug Eluting Stents (DES)

2.3.2.2.1 Drugs Used in DES

2.3.3 Intravascular Imaging

2.3.3.1 Intravascular Ultrasound (IVUS)

2.3.3.2 Optical Coherence Tomography (OCT)

2.3.3.3 Fractional Flow Reserve (FFR)

2.4 Regulation of Interventional Cardiology Devices

2.4.1 The US Regulation System

2.4.2 The European Regulation System

2.4.2.1 Post Marketing Surveillance in the EU

3. The Global Interventional Cardiology Devices Market, 2010-2021

3.1 Interventional Cardiology Devices: Market Overview

3.1.1 Size of the Interventional Cardiology Devices Market in 2010

3.2 Regional Market Breakdown, 2010

3.2.1 The US, European and Japanese Markets

3.2.2 The Chinese and Indian Markets

3.3 Global Interventional Cardiology Devices Market Forecast, 2011-2015

3.4 Global Interventional Cardiology Devices Market Forecast, 2015-2021

3.5 Leading National Markets for Interventional Cardiology Devices: Sales Forecasts, 2011-2021

3.5.1 The US, European and Japanese Markets, 2011-2021

3.5.1.1 The US Market

3.5.1.2 The European Markets

3.5.1.3 The Japanese Market

3.5.2 The Chinese and Indian Markets, 2011-2021

3.5.2.1 The Chinese Market

3.5.2.2 The Indian Market

4. The Coronary Stent Market, 2010-2021

4.1 Chapter Overview

4.1.1 Coronary Stent Market in 2010: Market Segments and Country/Regional Breakdown

4.1.2 Coronary Stent Market Forecast, 2011-2021

4.2 The DES Market

4.2.1 The DES Market in 2010

4.2.2 The DES Market Forecast, 2011-2015

4.2.3 The DES Market Forecast, 2015-2021

4.3 Leading Coronary Stents: Product Analysis

4.3.1 Cypher Sirolimus-Eluting Stent (Cordis, a wholly owned subsidiary of Johnson and Johnson)

4.3.2 Taxus Paclitaxel-Eluting Stent (Boston Scientific)

4.3.2.1 Disputes Over Paclitaxel-Eluting Stents

4.3.3 Promus Everolimus-Eluting Stent (Boston Scientific)

4.3.4 Xience V Everolimus-Eluting Stent (Abbott Vascular)

4.3.5 Endeavor (Medtronic)

4.3.6 BioMatrix (Biosensors International)

4.4 The Coronary Stent Pipeline

4.4.1 Jactax (Boston Scientific)

4.4.2 MiStent (MiCell Technologies)

4.4.3 Synergy (Boston Scientific)

4.4.4 BioFreedom (Biosensors International)

4.4.5 VESTAsync (MIV Therapeutics)

4.4.6 Catania (CeloNova BioSciences)

4.4.7 Genous Combo (OrbusNeich)

4.5 Bioabsorbable Drug Eluting Stents

4.6 SWOT Analysis of the DES Market, 2011-2021

4.6.1 Strengths

4.6.1.1 DES Are More Effective Than BMS

4.6.1.2 Continuous Innovation

4.6.1.3 Continuously-Evolving Market

4.6.2 Weaknesses

4.6.2.1 Stent Thrombosis

4.6.2.2 The Success of DES Compared with Other Treatments

4.6.3 Opportunities

4.6.3.1 Increase in Coronary Artery Disease

4.6.3.2 Moving Away from Dual Antiplatelet Therapy

4.6.4 Threats

4.6.4.1 Small Number of Companies Operating in the US and Japan

4.6.4.2 The Drug May Become More Important Than the Stent

4.6.4.3 The DES Market is Still Emerging

5. The PTCA Balloon Market, 2010-2021

5.1 PTCA Balloon: Market Overview

5.1.1 PTCA Balloon Market is Dominated by Four Companies, 2010

5.1.2 PTCA Balloon Market Forecast, 2011-2021

5.2 PTCA Balloon Pipeline

5.2.1 Drug Eluting Balloons (DEBs)

5.2.2 DEB Market Forecast, 2011-2021

5.2.3 DEBs Currently in Development

5.2.3.1 ELUTAX (Aachen Resonance)

5.2.3.2 SeQuent Please (B.Braun Melsungen)

5.2.3.3 DIOR (Eurocor)

5.2.3.4 IN.PACT Amphirion (Invatec)

5.2.3.5 Moxy (Lutonix)

5.2.3.6 Pantera Lux (Biotronik)

5.3 SWOT Analysis of the PTCA Balloon Market, 2011-2021

5.3.1 Strengths

5.3.1.1 Well Established, Mature Sector of the Market

5.3.1.2 May Avoid the Need for a Permanent Coronary Stent and Dual Antiplatelet Therapy

5.3.2 Weaknesses

5.3.2.1 Standard PTCA has a High Rate of Restenosis

5.3.2.2 Only a Small Number of Companies Operate in the Market

5.3.3 Opportunities

5.3.3.1 Controversy Regarding Stent Safety

5.3.3.2 Rise in the Number of People with Coronary Artery Disease (CAD)

5.3.4 Threats

5.3.4.1 Drugs and Stents Could Become More Important than PTCA Balloon Procedures

5.3.4.2 The DEB Market is Still Emerging

6. The Intravascular Imaging Market, 2010-2021

6.1 The Intravascular Imaging Market in 2010

6.2 Intravascular Imaging Forecast, 2011-2015

6.3 Intravascular Imaging Forecast, 2015-2021

6.4 Intravascular Imaging Pipeline

6.4.1 Next Generation Imaging Technologies

6.4.1.1 High-Definition Intravascular Ultrasound (Silicon Valley Medical Instruments)

6.4.1.2 High-Resolution MicroOCT (Centre for Photomedicine at Massachusetts General Hospital)

6.4.1.3 Forward Looking Intravascular Ultrasound (FLIVUS) (Volcano Corporation)

6.4.1.4 Virtual Histology Intravascular Ultrasound (VH IVUS) (Volcano Corporation)

6.4.2 Multimodality Imaging

6.4.2.1 Lipiscan (InfraReDx)

6.4.2.2 Intravascular Ultrasound Optical Coherence Tomography Imaging System (University of California at Irvine)

6.4.3 Image Guided Therapies

6.4.3.1 Vibe RX Vascular Imaging Balloon Catheter (Volcano Corporation)

6.5 SWOT Analysis of the Intravascular Imaging Market, 2011-2021

6.5.1 Strengths

6.5.1.1 Provides Cardiologists with Useful Information

6.5.1.2 Higher Resolution Image than Coronary Angiography

6.5.1.3 Strong Intravascular Imaging Pipeline

6.5.2 Weaknesses

6.5.2.1 Expensive Technology That May Limit its Appeal

6.5.2.2 Adds Significant Time and Risk to the Procedure

6.5.3 Opportunities

6.5.3.1 Image Guided Therapy Offers Higher Efficacy than Stenting Alone

6.5.3.2 Increasing Prevalence of Coronary Artery Disease

6.5.4 Threats

6.5.4.1 Small Number of Companies Operate in the Market

6.5.4.2 Low Reimbursement Rates Threaten to Prevent Widescale Use

7. Interventional Cardiology Devices Market: Analysis by Company, 2010

7.1 Boston Scientific

7.1.1 Boston Scientific Interventional Cardiology Sales, 2010

7.1.2 Boston Scientific Interventional Cardiology Rankings, 2010

7.1.3 Boston Scientific Pipeline

7.2 Abbott Vascular

7.2.1 Abbott Vascular Sales, 2010

7.2.2 Abbott Vascular Interventional Cardiology Rankings, 2010

7.2.3 Abbott Vascular Pipeline

7.3 Medtronic

7.3.1 Medtronic Sales, 2010

7.3.2 Medtronic Interventional Cardiology Rankings, 2010

7.3.3 Medtronic Pipeline

7.4 Volcano Corporation

7.4.1 Volcano Corporation Sales, 2010

7.4.2 Volcano Corporation Interventional Cardiology Ranking, 2010

7.4.3 Volcano Corporation Pipeline

7.5 Cordis Corporation (a Johnson & Johnson Company)

7.5.1 Cordis Sales, 2010

7.5.2 Cordis Rankings, 2010

7.5.3 Cordis Pipeline

7.6 St. Jude Medical

7.6.1 St. Jude Medical Sales, 2010

7.6.2 St. Jude Medical Pipeline

8. Expert Opinions

8.1 Interview with Guillermo Tearney, Professor of Pathology at The Wellman Centerfor Photomedicine, Harvard Medical School

8.1.1 The Intravascular Imaging Market

8.1.2 The Novel MicroOCT System Currently being Developed by Professor Tearney at Harvard University

8.1.3 The International Working Group for Intracoronary OCT Standardization and Validation

8.2 Interview with Zhongping Chen, Professor of Biomedical Engineering at Universityof California

8.2.1 The Intravascular Imaging Market

8.2.2 The Combined IVUS/OCT System Currently being Developed by Professor Chen at the University of California

9. Conclusions

9.1 The Interventional Cardiology Devices Market, 2011-2021

9.1.1 Growth will be Driven by Emerging Markets

9.2 The Coronary Stent Market, 2011-2021

9.2.1 Innovation Will Drive Growth in the DES Market

9.2.2 DES May Be Challenged by Other Stenting Technologies

9.3 The PTCA Balloon Market, 2011-2021

9.3.1 DEBs Will See Rapid Growth

9.4 The Intravascular Imaging Market, 2011-2021

Appendix A

Appendix B

Visiongain report evaluation form

List of Tables

Table 2.1 The Cardiology Device Market ($bn) by Sector, 2010

Table 2.2 Advantages and Disadvantages of Interventional Cardiology

Table 3.1 The Interventional Cardiology Devices Market ($bn) by Segments, 2010

Table 3.2 Leading National Markets for Interventional Cardiology Devices ($bn), 2010

Table 3.3 Global Interventional Cardiology Devices Market Forecast ($bn), 2010-2021

Table 3.4 Leading Interventional Cardiology Devices National Market Forecasts ($bn), 2010-2015

Table 3.5 Leading Interventional Cardiology Devices National Market Forecasts ($bn), 2015-2021

Table 3.6 Chinese Interventional Cardiology Devices Market: Drivers and Restraints, 2011-2021

Table 4.1 The DES and BMS Market: Sales ($bn) and Market Share (%), 2010

Table 4.2 The Coronary Stent Market ($bn) by Country/Region, 2010

Table 4.3 The Coronary Stent Market Forecast ($bn), 2010-2015

Table 4.4 The Coronary Stent Market Forecast ($bn), 2015-2021

Table 4.5 Leading Products in the DES Market: Sales ($m) and Market Share (%), 2010

Table 4.6 The DES Market Forecast ($bn), 2010-2015

Table 4.7 The DES Market Forecast ($bn), 2015-2021

Table 4.8 Driver and Restraints in the DES Market, 2011-2015

Table 4.9 Coronary Stents Development Pipeline, 2011

Table 4.10 SWOT Analysis of the DES Market, 2011-2021

Table 5.1 Leading Companies in the PTCA Balloon Market ($bn), 2010

Table 5.2 The PTCA Balloon Market Forecast ($bn), 2010-2015

Table 5.3 The PTCA Balloon Market Forecast ($bn), 2015-2021

Table 5.4 Advantages and Disadvantages of DEBs

Table 5.5 The DEB Market Forecast ($bn), 2010-2015

Table 5.6 The DEB Market Forecast ($bn), 2015-2021

Table 5.7 The DEBs Currently on the Market or in Development, 2011

Table 5.8 SWOT Analysis of the PTCA Balloon Market, 2011-2021

Table 6.1 The Intravascular Imaging Market ($bn) by Segment, 2010

Table 6.2 IVUS Market Share (%) of Volcano Corporation and Boston Scientific by Regions, 2010

Table 6.3 The Intravascular Imaging Market Segments Forecasts ($bn), 2010-2015

Table 6.4 The Intravascular Imaging Market Segments Forecasts ($bn), 2015-2021

Table 6.5 Intravascular Imaging Pipeline, 2011

Table 6.6 SWOT Analysis of the Intravascular Imaging Market, 2011-2021

Table 7.1 Boston Scientific Sales ($bn) by Business Segment, 2010

Table 7.2 Boston Scientific Coronary Stent Sales ($m), 2009 and 2010

Table 7.3 Boston Scientific Rankings by Sales, 2010

Table 7.4 Abbott Laboratories Sales ($bn) by Business Segment, 2010

Table 7.5 Abbott Vascular Rankings by Sales, 2010

Table 7.6 Medtronic Sales ($bn) by Business Segment, 2010 and 2009

Table 7.7 Medtronic Rankings by Sales, 2010

Table 7.8 Volcano Corporation Sales ($m) by Region, 2010 and 2009

Table 7.9 Volcano Corporation Sales ($m) by Business Segment, 2010

Table 7.10 Volcano Corporation Ranking by Sales, 2010

Table 7.11 Cordis Rankings by Sales, 2010

Table 7.12 St. Jude Medical Sales ($bn) by Segment, 2010

Table 9.1 Global Interventional Cardiology Devices Market: Drivers and Restraints, 2011-2021

List of Figures

Figure 2.1 Market Shares (%) of the Leading Sectors in the Cardiology Device Market, 2010

Figure 3.1 The Interventional Cardiology Devices Market Share (%) by Segments, 2010

Figure 3.2 The Interventional Cardiology Devices Market ($bn) by Segments, 2010

Figure 3.3 The Interventional Cardiology Devices Market Shares (%) in Leading National Markets, 2010

Figure 3.4 Leading National Markets for Interventional Cardiology Devices ($bn), 2010

Figure 3.5 Global Interventional Cardiology Devices Market Forecast ($bn), 2010-2015

Figure 3.6 Global Interventional Cardiology Devices Market Forecast ($bn), 2015-2021

Figure 3.7 The US Interventional Cardiology Devices Market Forecast ($bn), 2010-2015

Figure 3.8 European Interventional Cardiology Devices Market Forecasts ($bn), 2010-2015

Figure 3.9 Asian Interventional Cardiology Devices Market Forecasts ($bn), 2010-2015

Figure 3.10 The US Interventional Cardiology Devices Market Forecast ($bn), 2015-2021

Figure 3.11 European Interventional Cardiology Devices Market Forecasts ($bn), 2015-2021

Figure 3.12 Asian Interventional Cardiology Devices Market Forecasts ($bn), 2015-2021

Figure 4.1 The DES and BMS Market Shares (%), 2010

Figure 4.2 Coronary Stent Market Share (%) by Country/Region, 2010

Figure 4.3 Total Coronary Stent Market Forecast ($bn), 2010-2015

Figure 4.4 Total Coronary Stent Market Forecast ($bn), 2015-2021

Figure 4.5 Market Shares (%) of Leading Products in the DES Market, 2010

Figure 4.6 The DES Market Forecast ($bn), 2010-2015

Figure 4.7 The DES Market Forecast ($bn), 2015-2021

Figure 4.8 Sales ($m) of Taxus Stents by Region, 2010

Figure 4.9 Sales ($m) of Promus Stents by Region, 2010

Figure 5.1 Market Shares (%) of Leading Companies in the PTCA Balloon Market, 2010

Figure 5.2 The PTCA Balloon Market Forecast ($bn), 2010-2015

Figure 5.3 The PTCA Balloon Market Forecast ($bn), 2010-2015

Figure 5.4 The DEB Market Forecast ($bn), 2010-2015

Figure 5.5 The DEB Market Forecast ($bn), 2015-2021

Figure 6.1 The Intravascular Imaging Market Share (%) by Segment, 2010

Figure 6.2 The US IVUS Market Shares (%) by Company, 2010

Figure 6.3 The Japanese IVUS Market Shares (%) by Company, 2010

Figure 6.4 European IVUS Market Shares by Company, 2010

Figure 6.5 Total Intravascular Imaging Market Forecast ($bn), 2010-2015

Figure 6.6 IVUS, OCT and FFR Market Forecasts ($bn), 2010-2015

Figure 6.7 Total Intravascular Imaging Market Forecast ($bn), 2015-2021

Figure 6.8 IVUS, OCT and FFR Market Forecasts ($bn), 2015-2021

Figure 7.1 Boston Scientific Sales Share (%) by Business Segment, 2010

Figure 7.2 Boston Scientific Global Coronary Stent Sales ($m), 2009 and 2010

Figure 7.3 Boston Scientific Coronary Stent Sales ($m) in the US, 2009 and 2010

Figure 7.4 Boston Scientific Coronary Stent Sales ($m) in Markets Outside the US, 2009 and 2010

Figure 7.5 Abbott Laboratories Sales Share (%) by Business Segment, 2010

Figure 7.6 Medtronic Sales Share (%) by Business Segment, 2010

Figure 7.7 Medtronic Sales ($bn) by Business Segment, 2010 and 2009

Figure 7.8 Medtronic Sales ($bn) by Region, 2010

Figure 7.9 Volcano Corporation Sales ($m) by Region, 2010 and 2009

Figure 7.10 Volcano Corporation Sales Share (%) by Region, 2010

Figure 7.11 Volcano Corporation Sales Share (%) by Segment, 2010

Figure 7.12 Cordis Corporation Share (%) of Medical Devices and Diagnostics Segment of J&J, 2010

Figure 7.13 St Jude Medical Sales Share (%) by Segment, 2010

Companies Listed

Aachen Resonance

Abbott Laboratories

Abbott Vascular

Angiotech Pharmaceuticals

Axsun Technologies 

B.Braun Melsungen

Bioabsorbable Vascular Solutions 

Biosensors International

Biotronik SE & Co

Blue Medical Devices

Boston Scientific

Bristol Myers Squibb

CeloNova BioSciences

Center for Devices and Radiological Health (CDRH).

Centre for Photomedicine at Massachusetts General Hospital

Circulatory System Devices Panel 

ClearStream Technologies

Conor Medsystems

Cordis Corporation

EU Council

Eurocor

Food and Drug Administration (FDA)

Guidant Corporation

Health Canada

InfraReDx

Insightra Medical

Invatec

Johnson & Johnson

JW Medical Systems

Kyoto Medical Planning Co Ltd

Labcoat Limited

LightLab Imaging

Lutonix

Medtronic

MiCell Technologies

MIV Therapeutics

National Institute of Biomedical Imaging and Bioengineering

National Institute of Clinical Excellence (NICE) [UK]

National Institute of Health (NIH) [US]

Novartis

Novelis

OCT Medical Imaging Inc

Opto Circuits ltd

OrbusNeich

Phillips Healthcare

REVA Medical

Sadra Medical 

Sanofi-Aventis

Silicon Valley Medical Instruments

St Jude Medical

St Michael's Hospital, Toronto

Terumo Corporation

The International Working Group for Intracoronary OCT Standardization and Validation

The Wellman Center for Photomedicine, Harvard Medical School

University of California at Irvine

Volcano Corporation

Wyeth Pharmaceuticals 

To order this report:

General Medicine and Specialty Medicine Industry: Interventional Cardiology Devices: World Market Prospects 2011-2021

General Medicine and Specialty Medicine Business News

More  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
2. Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
3. Society of Interventional Radiology Addresses Radiation Safety, Advances Best Practices
4. Reportlinker Adds Neurology Devices Market Outlook in United States to 2017 - Neurostimulation Devices, Interventional Neurology and Others
5. Brainlab and SurgiVision Announce Strategic Alliance in MRI-Guided Drug Delivery and Other Interventional MRI Technologies in Neurosurgery
6. Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries)
7. Fueling Interventional Radiology Growth: SIR Foundation Announces Navilyst Medical Pledge
8. MEDRAD® Announces New Head of Interventional Business
9. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
10. Reportlinker Adds Overview of the Western European Peripheral Interventional Devices Market
11. Interventional Spine®, Inc. Appoints Stephen Colaiezzi, Senior Vice President, Strategic Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... Feb. 11, 2016  Walgreens has committed to provide ... and Washington, D.C. as part of ... was commended by shareholder advocacy organization As You Sow. ... Sow. "Many people hold on to unneeded drugs because they ... tragic consequences." --> Conrad MacKerron , Senior ...
(Date:2/11/2016)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... other birth tissues, human skin and bone, and patent-protected ... products and therapies, announced today that it will present ... in New York , NY.  Parker ... Senken , Chief Financial Officer and Chris Cashman ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric ... to improve care by making data on heart procedures public and easily understandable ... Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes will bring ...
(Date:2/11/2016)... Washington, DC (PRWEB) , ... February 11, 2016 ... ... announce an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study ... a not-for-profit Catholic health care system that’s partnering with Intel on value-based health ...
(Date:2/11/2016)... ISLAND, Australia (PRWEB) , ... February 11, 2016 ... ... full potential ?" motivational speaker, trainer and author Ray Clarke poses a question ... personal fulfillment . In his book, "Being in the Being" (published by ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... of a master charity program created to assist the people of their local ... closely with nonprofit organizations and community leaders. Their hope is to bring awareness ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix ... Family Practice , will be presenting at the 2016 HIMSS Annual Conference & ... , During his session, “ Coding for Care: Using Data Analytics for ...
Breaking Medicine News(10 mins):